Journal of Neuro-Oncology

, Volume 104, Issue 1, pp 83–92

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy

  • Xinmei Zhu
  • Mitsugu Fujita
  • Linda A. Snyder
  • Hideho Okada
Laboratory Investigation - Human/Animal Tissue

Abstract

Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) inhibit anti-tumor immune responses and facilitate tumor growth. Precursors for these immune cell populations migrate to the tumor site in response to tumor secretion of chemokines, such as monocyte chemoattractant protein-1 (MCP-1/CCL2), which was originally purified and identified from human gliomas. In syngeneic mouse GL261 glioma and human U87 glioma xenograft models, we evaluated the efficacy of systemic CCL2 blockade by monoclonal antibodies (mAb) targeting mouse and/or human CCL2. Intraperitoneal (i.p.) administration of anti-mouse CCL2 mAb as monotherapy (2 mg/kg/dose, twice a week) significantly, albeit modestly, prolonged the survival of C57BL/6 mice bearing intracranial GL261 glioma (P = 0.0033), which was concomitant with a decrease in TAMs and MDSCs in the tumor microenvironment. Similarly, survival was modestly prolonged in severe combined immunodeficiency mice bearing intracranial human U87 glioma xenografts treated with both anti-human CCL2 mAb and anti-mouse CCL2 antibodies (2 mg/kg/dose for each, twice a week) compared to mice treated with control IgG (P = 0.0159). Furthermore, i.p. administration of anti-mouse CCL2 antibody in combination with temozolomide (TMZ) significantly prolonged the survival of C57BL/6 mice bearing GL261 glioma with 8 of 10 treated mice surviving longer than 70 days, while only 3 of 10 mice treated with TMZ and isotype IgG survived longer than 70 days (P = 0.0359). These observations provide support for development of mAb-based CCL2 blockade strategies in combination with the current standard TMZ-based chemotherapy for treatment of malignant gliomas.

Keywords

Glioma Chemokine CCL2 Monoclonal antibody Chemotherapy Temozolomide 

Abbreviations

BIL

Brain infiltrating lymphocyte

CNS

Central nervous system

mAb

Monoclonal antibody

References

  1. 1.
    Mizutani K, Sud S, McGregor NA et al (2009) The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11:1235–1242PubMedGoogle Scholar
  2. 2.
    Huang B, Lei Z, Zhao J et al (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252:86–92PubMedCrossRefGoogle Scholar
  3. 3.
    Vanderkerken K, Vande BI, Eizirik DL et al (2002) Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 19:87–90PubMedCrossRefGoogle Scholar
  4. 4.
    Ohta M, Kitadai Y, Tanaka S et al (2002) Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 102:220–224PubMedCrossRefGoogle Scholar
  5. 5.
    Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N (1998) Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194:335–340PubMedGoogle Scholar
  6. 6.
    Lebrecht A, Grimm C, Lantzsch T et al (2004) Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 25:14–17PubMedCrossRefGoogle Scholar
  7. 7.
    Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ (2007) CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9:556–562PubMedCrossRefGoogle Scholar
  8. 8.
    Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727–740PubMedCrossRefGoogle Scholar
  9. 9.
    Sweet MJ, Campbell CC, Sester DP et al (2002) Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages. J Immunol 168:392–399PubMedGoogle Scholar
  10. 10.
    Scholl SM, Pallud C, Beuvon F et al (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86:120–126PubMedCrossRefGoogle Scholar
  11. 11.
    Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174PubMedCrossRefGoogle Scholar
  12. 12.
    Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26:373–400PubMedCrossRefGoogle Scholar
  13. 13.
    Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59(10):1593–1600PubMedCrossRefGoogle Scholar
  14. 14.
    Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ (1989) Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 169:1449–1459PubMedCrossRefGoogle Scholar
  15. 15.
    Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ (1989) Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol 142:1956–1962PubMedGoogle Scholar
  16. 16.
    Graeber MB, Scheithauer BW, Kreutzberg GW (2002) Microglia in brain tumors. GLIA 40:252–259PubMedCrossRefGoogle Scholar
  17. 17.
    Takeshima H, Kuratsu J, Takeya M, Yoshimura T, Ushio Y (1994) Expression and localization of messenger RNA and protein for monocyte chemoattractant protein-1 in human malignant glioma. J Neurosurg 80:1056–1062PubMedCrossRefGoogle Scholar
  18. 18.
    Desbaillets I, Tada M, De Tribolet N, Diserens AC, Hamou MF, Van Meir EG (1994) Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer 58:240–247PubMedCrossRefGoogle Scholar
  19. 19.
    Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST (1997) Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol (Berl) 93:518–527CrossRefGoogle Scholar
  20. 20.
    Jordan JT, Sun W, Hussain SF, Deangulo G, Prabhu SS, Heimberger AB (2008) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57:123–131PubMedCrossRefGoogle Scholar
  21. 21.
    Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, Ushio Y (1993) Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst 85:9–1836CrossRefGoogle Scholar
  22. 22.
    Platten M, Kretz A, Naumann U et al (2003) Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 54:388–392PubMedCrossRefGoogle Scholar
  23. 23.
    Loberg RD, Ying C, Craig M et al (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67:9417–9424PubMedCrossRefGoogle Scholar
  24. 24.
    Tsui P, Das A, Whitaker B et al (2007) Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies. Hum Antibodies 16:117–125PubMedGoogle Scholar
  25. 25.
    Carton JM, Sauerwald T, Hawley-Nelson P et al (2007) Codon engineering for improved antibody expression in mammalian cells. Protein Expr Purif 55:279–286PubMedCrossRefGoogle Scholar
  26. 26.
    Fujita M, Zhu X, Sasaki K et al (2008) Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 180:2089–2098PubMedGoogle Scholar
  27. 27.
    Nishimura F, Dusak JE, Eguchi J et al (2006) Adoptive transfer of Type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 66:4478–4487PubMedCrossRefGoogle Scholar
  28. 28.
    Sasaki K, Zhu X, Vasquez C et al (2007) Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 67:6451–6458PubMedCrossRefGoogle Scholar
  29. 29.
    Zhu X, Nishimura F, Sasaki K et al (2007) Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 5:10PubMedCrossRefGoogle Scholar
  30. 30.
    Zhu X, Fallert-Junecko BA, Fujita M et al (2010) Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 59:1401–1409PubMedCrossRefGoogle Scholar
  31. 31.
    Lewis C, Murdoch C (2005) Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 167:627–635PubMedCrossRefGoogle Scholar
  32. 32.
    Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG (2004) Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 70:229–243PubMedCrossRefGoogle Scholar
  33. 33.
    Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7:134–153PubMedCrossRefGoogle Scholar
  34. 34.
    Stupp R, Dietrich PY, Ostermann KS et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRefGoogle Scholar
  35. 35.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  36. 36.
    Ueda R, Fujita M, Zhu X et al (2009) Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 15:6551–6559PubMedCrossRefGoogle Scholar
  37. 37.
    Fridlender ZG, Buchlis G, Kapoor V et al (2010) CCL2 blockade augments cancer immunotherapy. Cancer Res 70:109–118PubMedCrossRefGoogle Scholar
  38. 38.
    Ford AL, Goodsall AL, Hickey WF, Sedgwick JD (1995) Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4 + T cells compared. J Immunol 154:4309–4321PubMedGoogle Scholar
  39. 39.
    Badie B, Schartner J (2001) Role of microglia in glioma biology. Microsc Res Tech 54:106–113PubMedCrossRefGoogle Scholar
  40. 40.
    Okada H, Kohanbash G, Zhu X et al (2009) Immunotherapeutic approaches for glioma. Crit Rev Immunol 29:1–42PubMedGoogle Scholar
  41. 41.
    Fujita M, Scheurer ME, Decker SA et al (2010) Role of type 1 IFNs in antiglioma immunosurveillance–using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res 16:3409–3419PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Xinmei Zhu
    • 1
    • 2
  • Mitsugu Fujita
    • 1
    • 2
  • Linda A. Snyder
    • 5
  • Hideho Okada
    • 1
    • 2
    • 3
    • 4
    • 6
  1. 1.Department of Neurological SurgeryUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Brain Tumor ProgramUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  3. 3.Department of SurgeryUniversity of Pittsburgh School of MedicinePittsburghUSA
  4. 4.Department of ImmunologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  5. 5.Ortho Biotech Oncology Research and Development, Centocor, IncRadnorUSA
  6. 6.G12a Research Pavilion at Hillman Cancer CenterPittsburghUSA

Personalised recommendations